ELElena G. Lileeva

Elena G. Lileeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena G. Lileeva has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Blockade of the STAT3 pathway as a method of targeted antitumor therapy

    by V. N. Fedorov, V. P. Vdovichenko, S. S. Petukhov, A. V. Arshinov, S. Sh. Suleymanov, E. G. Lileeva, В. Н. Фёдоров, В. П. Вдовиченко, С. С. Петухов, А. В. Аршинов, et al.

    Introduction . Cancer remains one of the most pressing medical and social problems, being a leading cause of disability and mortality worldwide. Contemporary antineoplastic pharmacotherapy is characterized by the development of novel therapeutic approaches, one of which has been the introduction of targeted therapy based on selective action on specific molecular targets critically important for the viability of tumor cells. Objective . To determine the role of the transcription factor STAT3 (Signal Transducer and Activator of Transcription 3) in tumor growth and to identify targeted therapeutic agents developed on the basis of its antagonists. Materials and methods . A narrative literature review was performed. PubMed/MEDLINE, eLIBRARY.RU and Google Scholar were searched for publications from 1997 to 2026 using the keywords “STAT3”, “JAK/STAT3”, “STAT3 inhibitor”, “STAT3 cancer” and their Russian equivalents. Original experimental and clinical studies, reviews, systematic reviews and meta-analyses published in English or Russian were included. Discussion . The principal groups of agents that block various steps of STAT3 activation include inhibitors of Janus kinases (JAK) (ruxolitinib, tofacitinib, fedratinib), inhibitors of the STAT3 SH2 domain (Stattic, S31-201, STA-21, BP-1-102), oligonucleotides (antisense and decoy oligonucleotides), and agents that prevent the binding of STAT3 to gene promoter regions. The main limitations of most of these agents include insufficient selectivity, pronounced toxicity, poor bioavailability, and the development of drug resistance. Novel delivery systems (including nanoparticles) and targeted protein degradation (PROTAC) are being developed to overcome them. A number of compounds are undergoing phase I–III clinical trials. Conclusion . The transcription factor STAT3 is one of the key regulators of tumor growth, angiogenesis, metastasis, and immune evasion. At the same time, STAT3 blockade represents a promising avenue in targeted antineoplastic therapy. Despite existing challenges, further study of the molecular biology of STAT3 and the improvement of targeted agents may lead to the development of selective and effective next-generation antineoplastic drugs.

  • Open Access

    Antiviral activity of new organophosphorus compounds in vitro

    by M. S. Zimin, E. G. Lileeva, М. С. Зимин, Е. Г. Лилеева

    Background. The search for new antiviral compounds is a priority due to growing pathogen resistance. Phosphonates, characterized by a stable carbon–phosphorus bond, represent a promising class of organophosphorus derivatives. However, data on the antiviral activity of newly synthesized phosphonates against alphaherpesviruses remain limited. Objective. To evaluate the cytotoxicity and antiviral activity of five novel phosphonates (SAN-1, SAN-2, SAN-3, SAN-4, and DII-C2) against pseudorabies virus (SuHV-1) in Vero cell culture. Methods. The infectious virus titer was determined using the Reed–Muench method. Cytotoxicity was assessed by visual microscopy and quantitative MTT assay after 72 h of incubation. Antiviral activity was evaluated by measuring the reduction of virus-induced cytopathic effect (CPE) and calculating virus titer reduction (log₁₀ TCID₅₀/mL) using the Spearman–Kärber method. All compounds were tested at a concentration range of 100–0.0001 μg/mL. Results. The SuHV-1 virus titer was 7.08±0.17 lg TCID₅₀/mL, confirming its suitability for screening. None of the tested phosphonates exhibited cytotoxicity at concentrations up to 100 μg/mL, with cell viability ranging from 92 to 96 % relative to untreated controls. Four compounds (SAN 2, SAN 3, SAN 4, and DII C2) showed pronounced antiviral activity, providing 72–82.5 % cell protection and reducing virus titers by 2.25–2.63 log₁₀. SAN 1 demonstrated weak activity (20 % protection). The highest efficacy was observed for DII C2 (82.5 % protection). Conclusion. SAN 2, SAN 3, SAN 4, and DII C2 exhibit low cytotoxicity and significant anti SuHV 1 activity in vitro. These compounds are promising candidates for further preclinical studies as potential antiviral agents.

  • Open Access

    Circulation of labeled medicinal products in clinical trials using digital tools

    by O. V. Sokolova, E. G. Lileeva, I. Yu. Isaeva, K. S. Alekseeva

    Background. Digitalization and the introduction of information technologies are transforming modern clinical research practices. Digital labeling of medicines ensures transparency and traceability of circulation, minimizes human errors in record-keeping, and increases the reliability of real-world clinical practice data in the Eurasian Economic Union (EAEU). These aspects are significant for the accelerated registration of medicines, amendments to the registration dossier, and the evaluation of post-registration monitoring data, including information on the results of any use of the investigational product. Objective . The purpose of this study is to identify the features of the circulation of labeled drugs in clinical trials, using calcium hydroxynicotinoylglutamate as a case study. Results . Clinical studies are conducted in medical institutions (both public and private), and the investigational drugs may or may not be included in the Russian Federation's digital marking system. The Rules of Good Clinical Practice provide for organizational measures during clinical studies for all participants. An open-label, two-stage comparative study was conduct ed in healthy volunteers. The pharmacokinetic characteristics, safety, and tolerability of hydroxynicotinoylglutamate calcium (5 mg/ml) were studied following intramuscular and intravenous administration. The logistics of the investigational drug are described across all business processes of the medical institution's inventory and accounting system, from acceptance at the research center to accountability and return to the sponsor. Conclusion . Digital technologies and the labeling of investigational drugs optimize control and accounting during clinical trials. At the same time, further study is needed on the integration of digital tools into the accounting systems of medical organizations.

  • Mixed anxiety-depressive disorder in the early period of ischemic stroke and its treatment with ampakines

    by A.L. Khokhlov, E.G. Lileeva, Yu.V. Rybachkova, Ch.A. Petrova, E.F. Oko, O.YU. Arseenkova, A.V. Kiselev

    Objective. Study of the efficacy of ampakins (Ampasse) in patients with anxiety and depressive disorders in the early recovery period of ischemic stroke (IS). Material and methods. The study included 203 patients with IS in the early recovery period who underwent rehabilitation measures at the Doctor Clinic medical facility (Tuimazy, Republic of Bashkortostan) in the period from January 2023 to August 2025. The study included patients with a history of IS no later than 3—6 months before the start date of the study, with signs of anxiety and depression of varying severity, who scored at least 8 points but no higher than 10 (the level of subclinically expressed symptoms) on the hospital anxiety and depression scale (HADS), as well as those who scored the required number of points on The Montreal Cognitive Function Assessment Scale (MoCA) (at least 10 points). The patients who met the inclusion criteria were randomly assigned to two groups: the experimental group and the control group. In the experimental group, 102 patients received Ampasse therapy in addition to standard therapy. The average age of these patients was 63±8.9 years, 48 of whom were women and 54 were men. In the control group, 101 patients received only basic therapy. The average age of the patients was 66±8.1 years), there were 45 women and 56 men. Throughout the study, the Beck anxiety, Beck depression, HADS, and the Spielberger-Khanin anxiety scales were also used. Results. The dynamics of improvement on all psychometric scales in the experimental group was statistically and clinically more pronounced than in the control group, which received only standard treatment. Conclusion. The results of this study demonstrated the positive effect of Ampasse on reducing the symptoms of anxiety and depression in patients after undergoing AI in the early recovery period.

  • Open Access

    Atmospheric pollution in Cherepovets according to remote sensing

    by Sophia A. Tsareva, Elena G. Lileeva, Yuri V. Tsarev, Nataliya S. Dybulina, Sabrina F. Velimetova, Царева Софья Александровна, Царев Юрий Валерьевич

    BACKGROUND: Satellite monitoring of air pollutant levels is currently widely used alongside conventional methods for assessing atmospheric pollution. Satellite technologies provide information on atmospheric pollutant levels for various geographic coordinate ranges; however, their applicability, notably for assessing air quality in residential areas, is disputed. AIM: The work aimed to assess atmospheric pollution in Cherepovets by comparing Sentinel-5P satellite data with Earth-based monitoring data. METHODS: The study assessed geospatial data on atmospheric air quality in Cherepovets. Sentinel-5P satellite data provided by the European Space Agency under the Copernicus program were analyzed using Google Earth Engine-based software. Satellite monitoring data were compared with those from the Severstal open service for atmospheric air quality monitoring in Cherepovets. RESULTS: Software for analyzing satellite monitoring data on atmospheric air quality in Cherepovets was developed using Google Earth Engine and JavaScript. Digital maps of nitrogen dioxide and sulfur dioxide atmospheric pollution were created. Satellite monitoring data were compared with Severstal's Earth-based monitoring data. CONCLUSION: Software for creating digital maps of atmospheric pollution by criteria pollutants (sulfur dioxide and nitrogen dioxide) has been developed. The differences between satellite and Earth-based monitoring data on atmospheric pollution in Cherepovets were analyzed.

  • Open Access

    Factors affecting the efficacy of drug therapy in patients with plaque psoriasis

    by A. L. Khokhlov, E. I. Samarina, E. G. Lileeva

    Relevance. The selection and modification of drug therapy for patients with plaque psoriasis does not have a specific solution for practicing specialists. Factors have been identified that can worsen the course of the disease when therapies with proven clinical efficacy are used and can even increase the severity and prevalence of the psoriatic process, leading to the development of erythroderma or resistance to the therapy. This article analyzed the actual clinical practice of plaque psoriasis therapy and the influence of concomitant diagnoses on the choice of therapy by physicians among patients who were treated in skin and venereal disease dispensaries in the Central Federal District from 2022 to 2023.Objective. To conduct a pharmacoepidemiological analysis of drug prescriptions and the volume of their consumption for plaque psoriasis using frequency analysis and analysis of average daily doses at the outpatient and inpatient stages of treatment, followed by a search for patterns.Materials and methods. An open, non-randomized, cross-sectional prospective study of outpatient records and hospital discharge summaries of 336 patients diagnosed with L40.0 plaque psoriasis was conducted over 2 years. Patients were surveyed by their physicians regarding their adherence to the physician recommendations using a questionnaire on adherence to therapy. The presence of complications of the primary diagnosis, concomitant diagnoses, and factors influencing the prescription of methotrexate and monoclonal antibodies were analyzed.Results. Patients prescribed methotrexate drugs had significantly more concomitant diseases (p Conclusions. Among patients prescribed genetically engineered drugs, concomitant complications of an arthropathic nature were significantly more common — in 32.5 % of cases, versus 18.2 % in the group of patients on methotrexate (p <0.05). Therefore, the choice in favor of monoclonal antibodies in most cases was due to the presence of arthropathic psoriatic complications, skin lesion severity, younger age, and high adherence to the innovative therapy prescribed by the doctor (p <0.05).

  • Open Access

    Clinical and economic aspects of chronic cerebral ischemia treatment

    by A. V. Kiselev, A. L. Khokhlov, S. V. Stovbun, S. A. Speshilova, E. G. Lileeva

    Клинико-экономические аспекты лечения хронической ишемии головного мозга

  • Open Access

    Assessment of the level of anxiety-depressive disorders, quality of life, and therapy adherence in patients with plaque psoriasis

    by A. L. Khokhlov, E. I. Samarina, E. G. Lileeva

    Relevance. The treatment of moderate and severe psoriasis poses significant challenges in clinical practice. This article is devoted to the analysis of real-world clinical practice in the treatment of plaque psoriasis, factors causing relapses of plaque psoriasis, the prevalence of anxiety and depressive disorders, and the assessment of the quality of life of patients with psoriasis using various systemic medications among patients who were observed in dermatovenereological dispensaries of the Central Federal District during the period 2022–2023.Objectives. To determine the optimal drug therapy for patients with plaque psoriasis based on comprehensive pharmacoepidemiological, clinical, compliance, and medication adherence assessments.Materials and methods. Retrospective comparative analysis of the medical records of 336 patients with plaque psoriasis (L40.0), moderate and severe. Two comparison groups: Group I — 166 patients receiving methotrexate and Group II — 170 patients receiving genetically engineered drugs. Patients were surveyed by physicians to confirm their therapy compliance. The levels of anxiety and depression were assessed using the HADS scale, and quality of life was assessed using the dermatological quality of life index — DLQI.Results. The highest rate of adherence to therapy (>80%) was recorded in the group of patients undergoing therapy with genetically engineered drugs and who had a high level of anxiety (r=0.202, pppConclusions. An increased level of anxiety in patients undergoing therapy with genetically engineered drugs increased their adherence to treatment (r=0.202, p<0.05). The worse the quality of life of patients undergoing therapy with genetically engineered drugs, the less adherence.

  • Clinical and economic analysis of the dynamics of quality of life of patients with plaque psoriasis in real clinical practice

    by А.л. Хохлов, Е.г. Лилеева, Е.и. Самарина

    если в результате проводимой терапии ухудшается качество жизни, полезность такого лечения для больного существенно снижается. Данная статья посвящена анализу реальной клинической практики лечения бляшечного псориаза и оценке дерматологического качества жизни больных псориазом при использовании различных системных лекарственных препаратов среди пациентов, наблюдаемых в кожно-венерологических диспансерах Центрального Федерального округа в период 2022-2023 г. Цель работы. Определить оптимальную лекарственную терапию пациентов с бляшечным псориазом на основе оценки дерматологического индекса качества жизни. Методология. Был проведен ретроспективный сравнительный анализ медицинской документации 171 пациентов со средней и тяжелой степенью тяжести бляшечного псориаза (L40.0). Две группы сравнения: I - пациенты, находящихся на терапии метотрексатом и II – пациенты, находящихся на терапии генно-инженерными лекарственными препаратами. Качество жизни пациентов, связанное со здоровьем, измерялось врачами по дерматологическому индексу качества жизни –DLQI. Результаты. Очень сильное влияние заболевания на жизнь пациентов, получающих метотрексат, было подтверждено средним баллом индекса качества жизни, составившим 12±6**(p <0,001). Среди пациентов, находящихся на терапии генно-инженерными лекарственными препаратами, заболевание не накладывало большого негативного эффекта на жизнь, средний показатель индекса DLQI составил 3±3,35**(p <0,001). Показатель «затраты/полезность» доказал ухудшение качества жизни при системной терапии метотрексатом. В группе пациентов, получающих такие генно-инженерную препараты (рисанкизумаб, гуселькумаб, секукинумаб, нетакимаб), показатели «затраты/полезность» были минимальны и показатели утилитарности составили: CURРИСА=18,69; CURГУС=47,81; CURСЕКУ=56,27; CURНЕТА =79,13. if quality of life deteriorates as a result of therapy, the benefit of such treatment for the patient is significantly reduced. This article is devoted to the analysis of real clinical practice in the treatment of plaque psoriasis and assessment of the dermatological quality of life of patients with psoriasis using various systemic medications among patients observed in dermatovenerological clinics of the Central Federal District in the period 2022-2023. Goal of the work. To determine the optimal drug therapy for patients with plaque psoriasis based on the assessment of the dermatological quality of life index. Methodology. A retrospective comparative analysis of the medical records of 171 patients with moderate to severe plaque psoriasis (L40.0) was conducted. Two comparison groups: I - patients on methotrexate therapy and II - patients on therapy with genetically engineered drugs. Patients' health-related quality of life was measured by physicians using the Dermatological Life Quality Index -DLQI. Results. The very strong impact of the disease on the lives of patients receiving methotrexate was confirmed by the mean quality of life index score of 12 ± 6** (p < 0.001). Among patients undergoing therapy with genetically engineered drugs, the disease did not have a large negative effect on life; the average DLQI index was 3±3.35**(p <0.001). The cost/benefit ratio demonstrated a deterioration in quality of life with systemic methotrexate therapy. In the group of patients receiving such genetically engineered drugs (risankizumab, guselkumab, secukinumab, netakimab), the cost/utility indicators were minimal and the utility indicators were: CURRISA=18.69; CURGUS=47.81; CURSECU=56.27; CURNETA =79.13.

  • Open Access

    Socio-Psychological Aspects of Introducing Mobile Technologies into Clinical Trials

    by Alexandr L. Khokhlov, Anna V. Andreenkova, Elena V. Dmitrieva, Mikhail V. Ilyin, Elena G. Lileeva, Petr A. Chizhov, Alexei E. Miroshnikov, Nikolay O. Pozdnyakov, Хохлов Александр Леонидович, Ильин Михаил Витальевич

    Background: High political and economic turbulence, changes in the international relations and cross-national economic ties enhance the demand for developing and launching new pharmacological treatments as a part of nationally independent health care program and import substitution policy. The number of clinical trials is growing rapidly, increasing the need for more effective solutions in organizing these trials optimizing the time, financial resources and efforts of medical personnel. The global trend of creating a new digital ecosystem in health care also raises the issues of higher patient involvement, taking into account the patient's psychological and physical barriers including the issues of personal data security. Aims: Evaluating the motivation and readiness of current clinical trials participants to switch to mobile technologies and identifying the barriers for these shifts. Method: The survey among 75 participants of clinical trials using offline self-completed questionnaire, data processing using statistical tools for data analysis. Results: Currently, 56% of respondents who are current participants of traditional medical trials would definitely agree to participate in mobile clinical trials. Compared to the consistency rate between traditional clinical trials estimated as 73%, the shift to a new format will result in 17% additional losses. The serious barrier for participation is the concerns about the security of personal information it is highly relevant for 37% of respondents and moderately relevant for 44%. The important motivating factor for the participation is the open access to personal medical data - 44% of respondents were highly interested in obtaining this data and 31% are somewhat interested. Conclusion. The results of the pilot study confirmed relatively high readiness of current participants to join mobile clinical trials and use mobile devices and solutions in future trials. However the level of readiness is unequal between different socio-demographic groups. Differentiating parameters are age, former experience of clinical trials and the skills in using digital technologies. Training programs for managers and researchers of clinical trials, provision of devices for non-users, timely technical support during the data collection and transparency in data usages can help to address key issues which slow down the peoples participation in mobile trials.